Catalent Pharma Solutions and Aegerion Pharmaceuticals, Inc. Partner on Launch of Newly FDA Approved JUXTAPID™

Published: Jan 08, 2013

SOMERSET, N.J.--(BUSINESS WIRE)--After a close 7-year partnership on clinical development, Catalent and Aegerion will partner for international supply for newly FDA approved JUXTAPID™ (lomitapide) capsules as an adjunct to a low-fat diet and other lipid-lowering treatments in patients with homozygous familial hypercholesterolemia (HoFH).

Back to news